Microglia Rescue Vulnerable Dopamine Neurons in Parkinson’s

 With your risk of Parkinsons' poststroke. How is your competent? doctor ensuring these microglia are working in your case?

Parkinson’s Disease May Have Link to Stroke March 2017 

The latest here: 

Microglia Rescue Vulnerable Dopamine Neurons in Parkinson’s

Summary:

Researchers at the University of Oxford have discovered that human microglia can selectively prune away toxic alpha-synuclein aggregates from dopamine-producing neurons without destroying the host nerve cells. Utilizing co-cultures of human induced pluripotent stem cell (iPSC)-derived neurons and microglia, the team demonstrated that microglia employ “trogocytosis”, a precise cellular nibbling mechanism, regulated by GPNMB, P2RY12, and CD22 signaling pathways, along with an IL-10 molecular brake. The findings identify a distinct, neuroprotective microglial subtype that shields neurons in Parkinson’s disease.

Key Facts:

• Selective Pruning via Trogocytosis: Human microglia selectively extract and dispose of aggregated alpha-synuclein clumps by “nibbling” specific segments of living dopamine neurons while preserving overall neuronal viability and connectivity.
• GPNMB Identified as Functional Driver: Glycoprotein non-metastatic melanoma protein B (GPNMB), a protein previously linked to Parkinson’s risk via genome-wide association studies (GWAS), binds directly to alpha-synuclein and is required for microglia to effectively clear aggregates.
• Fine-Tuned Immune Brakes: The protective clearance mechanism is controlled by sensing receptors (P2RY12), inhibitory checkpoints (CD22), and an interleukin-10 (IL-10) autocrine brake that prevents runaway neurotoxic inflammation.

Source: University of Oxford

Beyond the Double-Edged Sword: A Precision Immune Defense

In neurodegenerative diseases, microglia, the central nervous system’s resident immune sentinels, are typically framed through a conflicted narrative. Under physiological conditions, they survey brain tissue, prune synapses, and clear cellular debris; during chronic neurodegeneration, their persistent activation drives inflammatory signaling cascades that accelerate neuronal death.

Nowhere has this paradox been more evident than in Parkinson’s disease, a condition affecting more than 10 million individuals globally. The disease is defined by the selective death of dopamine-producing neurons within the substantia nigra, driven largely by the misfolding and aggregation of alpha-synuclein into toxic intracellular clumps.

Whether human microglia can intervene constructively to rescue dopamine neurons from this proteinaceous burden, without destroying the neurons in the process, has remained an open question.

Now, a team of neuroscientists at the University of Oxford has revealed an unexpected, highly targeted defense mechanism.

The researchers established that a specialized population of human microglia actively extracts and destroys harmful alpha-synuclein aggregates directly from living dopamine neurons via trogocytosis (from the Greek trogo, meaning “to gnaw” or “to nibble”).

“What is striking is the precision of this response,” said first author Hung-Ju Chueh, Ph.D., of the University of Oxford. “The microglia were not simply engulfing damaged neurons but instead removing parts of the neuron containing aggregated alpha-synuclein, suggesting that, at certain stages of disease, microglia help neurons dispose of potentially harmful material.”

Engineering Human iPSC Co-Cultures to Model Live Interactions

To investigate interactions between human brain cells in real time, the Oxford investigators generated human induced pluripotent stem cell (iPSC) lines, co-culturing authentic human dopamine neurons alongside human microglia.

The team modeled alpha-synuclein pathology through two complementary methods: by introducing genetic alpha-synuclein gene dosage elevations (triplication), and by seeding the cultures with exogenous preformed alpha-synuclein fibrils that template the misfolding of native neuronal protein.

High-resolution cellular imaging revealed that rather than engulfing entire dying neurons via standard phagocytosis, the microglia selectively nibbled off membrane pockets enclosing the aggregated protein. This process of trogocytosis eliminated the toxic pathology while leaving the broader axonal network and cell body intact.

Single-cell RNA sequencing showed that this clearance was driven by a distinct, transcriptionally defined subpopulation of activated microglia. This subset was kept from over-activating through a balanced signaling network:

• Surveillance and Guidance: Governed by P2RY12 purinergic receptor sensing.
• Cellular Checkpoints: Regulated by CD22 inhibitory surface interactions between neurons and microglia.
• Inflammatory Suppression: Maintained by an autocrine interleukin-10 (IL-10) brake that halted secondary, collateral inflammatory tissue injury.

Solving the GPNMB Genetic Mystery in Parkinson’s

The investigation also cracked a longstanding genetic puzzle. Multiple large-scale genome-wide association studies (GWAS) had previously flagged variants in the GPNMB (glycoprotein non-metastatic melanoma protein B) gene locus as significant risk factors for Parkinson’s disease, but its mechanistic function in the brain remained unknown.

The Oxford team discovered that GPNMB is directly upregulated in human microglia when exposed to aggregate-bearing neurons, where it physically interacts with pathological alpha-synuclein within the microglial machinery.

Furthermore, post-mortem analysis of human brain tissue from patients with incidental Lewy body disease and confirmed Parkinson’s disease revealed elevated GPNMB levels within substantia nigra microglia.

To confirm causality, the team used CRISPR interference (CRISPRi) to knock down GPNMB expression in human microglia. Deprived of GPNMB, the microglia lost their ability to clear alpha-synuclein aggregates from the neighboring dopamine neurons, establishing GPNMB as an essential driver of the neuroprotective response.

“Our findings highlight that the immune response in Parkinson’s disease is more nuanced than simply being beneficial or harmful,” noted senior author George Tofaris, M.D., Ph.D., Professor of Neurology and Translational Neuroscience at the University of Oxford. “We have identified a population of human microglia that can actively remove pathological alpha-synuclein from neurons. Understanding how to enhance and monitor such beneficial microglial functions, without triggering damaging inflammation, could open up new avenues for developing disease-modifying treatments.”

Editorial Notes:

• This article was edited by a Neuroscience News editor.
• Journal paper reviewed in full.
• Additional context added by our staff.

About this Neurology Research:

• Media Contact: Christopher McIntyre
• Source: University of Oxford
• Image Credit: Image credited to Neuroscience News
• Original Research is Open Access: Science Translational Medicine (Oct 7, 2026). “Human microglia clear intraneuronal alpha- synuclein aggregates by GPNMB-mediated trogocytosis.” Authors: Hung-Ju Chueh, Antigoni Katsikoudi, Ana Aragón-González, Chor Lai Lam, Liezel Tamon, Ashwin Jainarayanan, Devika Agarwal, Sally A. Cowley, David Sims, and George K. Tofaris.
• DOI: 10.1126/scitranslmed.adz9258

How Neurons Decline as Parkinsons Develops

 Is your competent? doctor closely following this because of your risk of Parkinsons post stroke? NO? So, you DON'T have a functioning stroke doctor, do you?

Parkinson’s Disease May Have Link to Stroke March 2017 

The latest here:

How Neurons Decline as Parkinsons Develops

Electrical activity dwindles in cells long before movement issues become visible.

It’s an unsettling thought: You could be walking around for 20 years developing Parkinson’s disease and not even know it.

And once symptoms appear, it’s too late for a cure.

What if a therapy that treats the root causes of Parkinson’s, not just the symptoms, could be started earlier?

Researchers in the School of Medicine at The University of Texas Health Science Center at San Antonio are studying changes in Parkinson’s-affected cells at various stages of the disease, long before any symptoms are evident. They describe the changes in an April issue of the Journal of Neuroscience.

The hope of the research is twofold: 1) gain understandings that can be used to formulate a drug to arrest the disease at a halfway point, and 2) lengthen the time when patients with Parkinson’s can lead healthy, productive lives.

Parkinson’s is marked by the degeneration and death of cells called dopamine neurons. These neurons are found in a brain structure called the substantia nigra. Image is for illustrative purposes only. Credit: Geoff B Hall.

Hidden changes

“For the first time we are getting a look at what’s going on in the time window before the disease visibly takes hold but while changes are occurring,” said study senior author Michael Beckstead, Ph.D., assistant professor of physiology and a member of the Barshop Institute for Aging and Longevity Studies at the UT Health Science Center.

Parkinson’s is marked by the degeneration and death of cells called dopamine neurons. These neurons are found in a brain structure called the substantia nigra. The Health Science Center researchers studied mice in which only these neurons are affected by a genetic mutation.

The MitoPark mouse, as it is called, is designed so that mitochondrial activity is hampered just in dopamine neurons of the substantia nigra. Mitochondria produce energy for our cells, and since these mice have impaired mitochondria, their dopamine neurons don’t make energy efficiently.

Mimics human Parkinson’s

At first, the mice are completely normal, but as weeks and months go by, the mutation causes their dopamine neurons to slowly become sick and die off. “It’s a progressive model in that these changes don’t take place overnight,” Dr. Beckstead said. “This makes it like the human disease, which is thought to be somewhere in the range of a 20-year process before symptoms become evident.”

In MitoPark mice, behavioral symptoms such as tremor start to manifest when the mice are about 20 weeks old. The UT Health Science Center study assessed functional status at time points before that — comparing dopamine neuron function at 6-10 weeks of age with function at 11-15 weeks of age and function at 16-plus weeks.

Timeline of decline

With these comparisons, the researchers constructed a timeline of functional decline in the dopamine neurons. They observed changes in three categories:

• Smaller dopamine neurons
• Reduced communication between the neurons
• Impaired electrical activity of the neurons

“Pretty much everything we measured declined in these cells,” Dr. Beckstead said. “It was really remarkable how everything we studied changed. It was a general decline, and these changes were all occurring before the animals were symptomatic, before you could detect any sort of deficit in their movement.”

In older mice starting to display the abnormal movements of the disease, the scientists made another observation — heightened gene expression to increase the electrical activity in the dopamine neurons.

“This is a late occurrence in the disease process,” Dr. Beckstead said. “We believe the cells are trying to compensate for the declining electrical activity. That’s probably how humans are able to be free of symptoms for so long when they have Parkinson’s, even though 30 percent or more of their dopamine neurons have died out.”

The study results aren’t going to translate into a clinical therapy any time soon, but such findings offer the promise that one day the root cause of Parkinson’s may be understood and treated.

Current treatments for Parkinson’s disease are all symptomatic. They focus on improving the movement deficits and making the patients more comfortable.

“We don’t have any treatments right now that actually affect the disease process,” Dr. Beckstead said. “The reason we don’t have any is we don’t understand what’s going on in the early stages of this disease. Studies such as ours will help fill in those knowledge gaps.”

About this genetics research

Funding: Grants from the William and Ella Owens Medical Research Foundation, the National Institutes of Health and the U.S. Department of Veterans Affairs supported this work.

Source: Will Sansom – UT Health Science Center San Antonio
Image Credit: The image is credited to Geoff B Hall and is in the public domain.
Original Research: Abstract for “Dopaminergic Neurons Exhibit an Age-Dependent Decline in Electrophysiological Parameters in the MitoPark Mouse Model of Parkinson’s Disease” by Sarah Y. Branch, Cang Chen, Ramaswamy Sharma, James D. Lechleiter, Senlin Li, and Michael J. Beckstead in Journal of Neuroscience. Published online April 6 2016 doi:10.1523/JNEUROSCI.1395-15.2016